Short Interest in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Drops By 54.0%

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) was the target of a large drop in short interest in February. As of February 13th, there was short interest totaling 9,071 shares, a drop of 54.0% from the January 29th total of 19,720 shares. Based on an average daily volume of 43,146 shares, the short-interest ratio is currently 0.2 days. Approximately 0.0% of the shares of the stock are short sold. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily volume of 43,146 shares, the short-interest ratio is currently 0.2 days.

Pharming Group Trading Down 0.4%

Shares of PHAR stock traded down $0.07 during mid-day trading on Friday, hitting $16.30. 10,117 shares of the company’s stock were exchanged, compared to its average volume of 33,741. The stock has a 50-day simple moving average of $17.58 and a two-hundred day simple moving average of $15.82. Pharming Group has a fifty-two week low of $7.50 and a fifty-two week high of $21.34. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of -1,628.37 and a beta of -0.01. The company has a quick ratio of 2.39, a current ratio of 3.16 and a debt-to-equity ratio of 0.35.

Institutional Investors Weigh In On Pharming Group

A number of institutional investors have recently bought and sold shares of the stock. NewEdge Advisors LLC increased its position in Pharming Group by 11,310.3% during the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after purchasing an additional 28,615 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of Pharming Group during the 4th quarter valued at $360,000. SmartHarvest Portfolios LLC acquired a new stake in shares of Pharming Group during the 4th quarter worth $224,000. Finally, EverSource Wealth Advisors LLC purchased a new position in shares of Pharming Group in the 2nd quarter worth $32,000. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on PHAR shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pharming Group in a report on Monday, December 22nd. Wall Street Zen raised Pharming Group to a “strong-buy” rating in a research note on Saturday, December 27th. Finally, Zacks Research downgraded shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.